Wells Fargo & Company MN trimmed its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 62.4% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 691,807 shares of the medical instruments supplier’s stock after selling 1,148,132 shares during the quarter. Wells Fargo & Company MN owned about 1.18% of OraSure Technologies worth $11,940,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. First Mercantile Trust Co. purchased a new position in OraSure Technologies in the 2nd quarter worth about $104,000. Victory Capital Management Inc. bought a new position in OraSure Technologies during the 1st quarter valued at about $100,000. Profund Advisors LLC bought a new position in OraSure Technologies during the 1st quarter valued at about $137,000. BNP Paribas Arbitrage SA lifted its stake in OraSure Technologies by 977.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock valued at $139,000 after acquiring an additional 9,723 shares during the period. Finally, Private Advisor Group LLC lifted its stake in OraSure Technologies by 7.1% during the 1st quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 723 shares during the period. Institutional investors own 92.10% of the company’s stock.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 22.81 on Tuesday. The company has a market capitalization of $1.36 billion, a P/E ratio of 42.16 and a beta of 1.55. The firm’s 50 day moving average price is $21.28 and its 200-day moving average price is $16.89. OraSure Technologies, Inc. has a 1-year low of $7.09 and a 1-year high of $22.94.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period in the prior year, the company earned $0.07 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. Analysts expect that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/10/03/orasure-technologies-inc-osur-shares-sold-by-wells-fargo-company-mn.html.

In related news, EVP Anthony Zezzo II sold 72,916 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the completion of the transaction, the executive vice president now owns 218,326 shares of the company’s stock, valued at $4,641,610.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Brian Smith sold 9,112 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $20.47, for a total transaction of $186,522.64. Following the transaction, the insider now owns 32,477 shares of the company’s stock, valued at $664,804.19. The disclosure for this sale can be found here. Insiders have sold 669,678 shares of company stock valued at $13,886,419 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

OSUR has been the topic of a number of recent analyst reports. Canaccord Genuity raised their price target on shares of OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, September 20th. Jefferies Group LLC reissued a “buy” rating and set a $20.00 price objective on shares of OraSure Technologies in a report on Tuesday, September 12th. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Stephens restated an “overweight” rating and set a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $18.04.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.